( MENAFN - GlobeNewsWire - Nasdaq) Allschwil, Switzerland – June 3, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data with daridorexant, Idorsia's dual orexin receptor antagonist for the treatment of adults with insomnia, will be presented at SLEEP 2024 – the 38th Annual Meeting of the Associated Professional Sleep Societies, taking place in Houston, Texas, from June 1– 5, 2024. Posters for daridorexant include the following: The abstracts can be found in the SLEEP 2024 Abstract supplement . In addition to the poster presentations, Idorsia is hosting a commercial and medical booth (#211) and a product theater at SLEEP 2024.
*This research is independent of Idorsia. Notes to the editor About daridorexant Daridorexant is Idorsia's dual orexin receptor antagonist (DORA) which blocks the binding of the wake-promoting orexin neuropeptides. Rather than inducing sleep through broad inhibition of brain activity, daridorexant only blocks the activation of orexin receptors.
Daridorexant is commercially available as QUVIVIQ in the US, Germany, Italy, Switzerland, Spain, the UK, Canada, Austria, and France, and is approved throughout the EU. About Idorsia Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia i.
